A report finds that hospitals make a lot of money marking up drugs and keep all those profits for themselves.
Physicians are spending less time with drug company sales reps, according to a new report.
A paper at the National Bureau of Economics examines how quickly changes in medical knowledge diffuse into practice.
According to a study, the price of treating multiple sclerosis with self-administered drugs increased more than four times between 2006 and 2016.
Prices for generic drugs have actually fallen fairly rapidly in recent years, according to a study from the National Bureau of Economic Research.
A paper from the Pacific Research Group finds that there are large potential savings from more, and more use of, biosimilars.
Research finds that payments and other benefits given by drug manufacturers to physicians does influence prescribing behavior.
A brief from the Kaiser Family Foundation describes prescription drug spending by payer type.
A large health plan’s program in incentivize doctors to use lower-cost oncology drugs shows little results.
IQVIA gives us its annual forecasting on prescription drug use for the next few years.
Using international reference pricing for drugs would save the United States a lot of money.
An article in Health Affairs proposes a standard for evaluating the “fairness” of drug pricing.
A new analysis finds that just a few drugs account for much of the growth in Medicare Part D spending.